Supplementary Materials

The PDF file includes:

  • Methods
  • Fig. S1. BCL3 predicts response to alkylating chemotherapy in GBM.
  • Fig. S2. BCL3 is relevant in LGGs and pan-glioma patients.
  • Fig. S3. Loss of BCL3 is a passenger event associated with survival.
  • Fig. S4. BCL-3 induces mesenchymal differentiation.
  • Fig. S5. BCL-3 promotes p65 nuclear translocation and NF-κB dimer exchange.
  • Fig. S6. CAII mediates BCL-3–dependent resistance to TMZ.
  • Fig. S7. ACZ chemosensitizes GBM xenografts to TMZ.
  • Fig. S8. Model demonstrating role of BCL-3 in promoting resistance to TMZ.
  • Table S1. Molecular profile of GBM cell lines.
  • Table S2. Cox regression analysis using different cutoff points for BCL3 expression in TCGA GBM patients.
  • Table S3. Multivariate Cox regression analysis in TCGA GBM patients treated with and without alkylating chemotherapy (TMZ).
  • Table S4. Clinical features of University of Chicago GBM patients.
  • Table S5. Cox regression analysis using different BCL3 expression cutoff points in TCGA LGG patients.
  • Table S6. Cox regression analysis in TCGA LGG patients with and without alkylating chemotherapy.
  • Table S7. Multivariate Cox regression analysis in patients from EORTC 26951 treated either with or without alkylating chemotherapy.
  • Table S8. Cox regression analysis of TCGA pan-glioma patients who received alkylating chemotherapy.
  • Table S9. Multivariate Cox regression of TCGA pan-glioma patients incorporating BCL3 CN.
  • Table S10. Multivariate Cox regression of TCGA pan-glioma patients incorporating BCL3 promoter methylation.
  • Table S11. Correlation between BCL3 mRNA expression and the expression of each MES or PN signature gene in TCGA GBM patients.
  • Legends for tables S12 and S13
  • Table S14. Oligonucleotides (oligos) for EMSA.
  • Table S15. ChIP primers and target gene κB sites.
  • Table S16. Oligonucleotide sequences for qPCR.
  • Legend for table S17
  • References (6072)

[Download PDF]

Other Supplementary Material for this manuscript includes the following:

  • Table S12. Genes that are up- and down-regulated (at least 1.5-fold) in U87 cells expressing si-BCL3 relative to those expressing si-control (see separate Excel file).
  • Table S13. Genes that are significantly (adjusted P < 0.05) up- and down-regulated in U87 cells expressing si-BCL3 or si-control after treatment with TMZ compared to vehicle (see separate Excel file).
  • Table S17. Raw data (see separate Excel file).